Long‐term treatment with desmopressin in children with primary monosymptomatic nocturnal enuresis: an open multicentre study

Authors:
  • EHE Hanson
    E Hanson
  • AHA L Hellström
    A L Hellström
  • SKS Kruse
    S Kruse
  • SGSillÉN on behalf of the Swedish Enuresis Trial (Sweet) Group
    SillÉN on behalf of the Swedish Enuresis Trial (Sweet) Group
Publisher website
Google Scholar
Abstract
Objective: To study the long‐term efficacy and safety of desmopressin treatment in children with primary monosymptomatic nocturnal enuresis. Patients and methods: Children (aged 6–12 years) with nocturnal enuresis were recruited into an open multicentre trial. All children underwent an observation period of 4 weeks before starting a 6‐week dose‐titration period with desmopressin. If the number of wet nights decreased by more than half during medication, they began long‐term treatment on 20–40 μg desmopressin. To test for cure and avoid overtreatment, the medication was interrupted for one week every third month. Results: Of the 399 children forming the intention‐to‐treat cohort, 245 halved their number of wet nights and started long‐term treatment. During the periods off medication, 77 children were dry and at the end of the study another 73 (still on medication) reduced the number of wet nights to ≤10% of that during the observation period. A further 51 children halved the number of wet nights compared with the observation period. No serious adverse events occurred. Conclusion: Long‐term treatment with nasal desmopressin at a main dose of 40 μg is an effective and safe treatment for monosymptomatic nocturnal enuresis.

This publication has 17 references indexed in Scilit: